Welcome to our dedicated page for Entasis Therapeutics Holdings news (Ticker: ETTX), a resource for investors and traders seeking the latest updates and insights on Entasis Therapeutics Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Entasis Therapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Entasis Therapeutics Holdings's position in the market.
Entasis Therapeutics (Nasdaq: ETTX) announced positive results from its Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR), achieving all endpoints for patients with carbapenem-resistant Acinetobacter infections. The company plans to submit an NDA mid-2022. The Phase 3 trial for zoliflodacin is expected to complete enrollment in 2023. Additionally, Entasis received a non-binding acquisition proposal from majority shareholder Innoviva, offering $1.80 per share. Despite a net loss of $47.1 million in 2021, the company is confident in its cash reserves to fund operations through Q3 2022.
Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) announced a preliminary proposal from majority stockholder Innoviva, Inc. to acquire all outstanding equity not owned by Innoviva, offering $1.80 per share in cash. The Board of Directors has retained MTS Health Partners and Covington & Burling to evaluate the proposal. This acquisition could have significant implications for shareholders, as Innoviva aims to consolidate its ownership of the clinical-stage biopharmaceutical company, which focuses on novel antibacterial products targeting multidrug-resistant infections.
Entasis Therapeutics Holdings announced its participation in the H.C. Wainwright BioConnect 2022 investor conference held virtually from January 10-13, 2022. The event will feature on-demand presentations starting January 10 and 1-on-1 investor meetings. A fireside chat is scheduled for January 10 with access via the event portal. Entasis focuses on developing novel antibacterial products targeting multidrug-resistant Gram-negative bacteria, with a pipeline including sulbactam-durlobactam for Acinetobacter baumannii and zoliflodacin for Neisseria gonorrhoeae.
Entasis Therapeutics Holdings announced compelling results from its Phase 3 ATTACK trial for its investigational drug, Sulbactam-durlobactam (SUL-DUR). The drug met all primary and secondary endpoints, showing significant improvement in 28-day all-cause mortality rates for patients with carbapenem-resistant Acinetobacter infections. The company reported a net loss of $12.4 million in Q3 2021, up from $11.1 million in Q3 2020, primarily due to increased administrative expenses. Cash reserves stood at $44.1 million, expected to fund operations until at least Q2 2022.
Entasis Therapeutics Holdings announced it will disclose its third quarter 2021 financial results on November 4, 2021, before market opening. A conference call and webcast will take place at 8:00 AM ET to discuss the results and provide updates on clinical and corporate matters, followed by a Q&A session. Investors can access the call by phone or through a provided link. Entasis focuses on developing innovative antibacterial products targeting serious infections from multidrug-resistant Gram-negative bacteria, with a pipeline that includes several advanced candidates.
Entasis Therapeutics Holdings Inc. (ETTX) announced positive topline results from its Phase 3 ATTACK trial, demonstrating statistical non-inferiority of SUL-DUR compared to colistin in treating Acinetobacter baumannii infections. The trial indicated a 19% mortality rate with SUL-DUR versus 32.3% with colistin, highlighting a 13.2% treatment difference. Additionally, SUL-DUR exhibited a reduction in nephrotoxicity from 37.6% with colistin to 13.2%. The company plans to submit a New Drug Application in mid-2022.
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. The company will present on September 30 at 1:20 p.m. EDT, featuring a company presentation and one-on-one investor meetings. A webcast of the presentation can be accessed on the company’s website. Entasis focuses on developing novel antibacterial products targeting serious infections caused by multidrug-resistant Gram-negative bacteria, with a pipeline that includes key candidates like sulbactam-durlobactam and zoliflodacin.
Entasis Therapeutics has published a profile of its antibiotic candidate ETX0462 in the journal Nature, marking a significant advancement in the fight against multidrug-resistant (MDR) Gram-negative infections. This first-in-class drug showcases unique properties, being unaffected by β-lactamases and demonstrating effective penetration into bacterial cells. The discovery emphasizes optimizing drug potency and reducing resistance. CEO Manos Perros highlighted the ongoing trials for other candidates, projecting promising outcomes for patients with bacterial infections.
Entasis Therapeutics Holdings (NASDAQ: ETTX) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The company will host a fireside chat available on-demand starting September 13 at 7:00 AM ET, alongside one-on-one investor meetings. Entasis focuses on developing novel antibacterial products targeting serious infections from multidrug-resistant Gram-negative bacteria, featuring a robust pipeline, including treatments for Acinetobacter baumannii and Neisseria gonorrhoeae.
Entasis Therapeutics (NASDAQ: ETTX) announced the completion of patient enrollment in the ATTACK Phase 3 trial for SUL-DUR, targeting carbapenem-resistant Acinetobacter infections. Top-line results are expected in early Q4 2021. The company has appointed Anna Diaz Triola as Chief Commercial Officer to enhance commercialization efforts. A $20 million private placement with Innoviva has bolstered cash reserves, expected to fund operations through Q2 2022. The Q2 2021 net loss was $12 million, a slight improvement from $13.4 million in Q2 2020, attributed to increased grant income.
